Investors keen on updates regarding the pending securities class action against Evolv Technologies Holdings, Inc. are prompted to liaise with Glancy Prongay & Murray LLP (“GPM”), the newly appointed Lead Counsel in the case.
Those who acquired shares in Evolv are encouraged to reach out to discuss the status of the litigation and the claims involved by contacting Charles H. Linehan, Esq. of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com.
On November 2, 2022, IPVM exposed Evolv for deceptive marketing practices, revealing collaboration with NCS4 to conceal failing weapon screening results. Consequently, Evolv’s stock plummeted by 2.7%.
Further turmoil ensued for Evolv on October 12, 2023, when the U.S. Federal Trade Commission probed the company’s marketing methods, leading to a 13.3% decrease in stock value.
A subsequent blow landed on February 20, 2024, as the U.S. Securities and Exchange Commission initiated a non-public inquiry, causing the stock to slide by 15.7%.
As the rollercoaster continued, on March 13, 2024, an independent entity disavowed Evolv’s earlier claims of technology validation, triggering a 3.5% drop in stock price.
The final nail in the coffin came on October 25, 2024, when Evolv declared a restatement of financial statements due to improper revenue recognition practices, leading to a colossal 40% plummet in stock value.
Stay tuned for developments on LinkedIn, Twitter, or Facebook.
Note: This document may be classified as Attorney Advertising in certain jurisdictions as per the relevant legal and ethical guidelines.